// Terumo Europe Congress Capture Demo â€” CIRSE 2025 Mock Data

export const CONGRESS_CONFIG = {
  id: 'cirse-2025',
  name: 'CIRSE 2025',
  fullName: 'Cardiovascular and Interventional Radiological Society of Europe Annual Congress 2025',
  location: 'Barcelona, Spain',
  dates: { start: '2025-09-13', end: '2025-09-17' },
  hashtags: ['#CIRSE2025', '#InterventionalOncology', '#TACE', '#Barcelona2025'],
  tracks: [
    { id: 'track-1', name: 'Interventional Oncology' },
    { id: 'track-2', name: 'Vascular Interventions' },
    { id: 'track-3', name: 'Embolization & Devices' },
    { id: 'track-4', name: 'Clinical Innovation & Imaging' },
  ],
  currentDay: 3,
  totalDays: 5,
};

export const KITS = [
  { id: 'kit-1', name: 'Competitive Landscape', shortName: 'COMP', color: '#00A8FF' },
  { id: 'kit-2', name: 'Combination Therapy', shortName: 'COMBO', color: '#9D4EDD' },
  { id: 'kit-3', name: 'Technical Innovation', shortName: 'TECH', color: '#FF3366' },
  { id: 'kit-4', name: 'Clinical Outcomes', shortName: 'CLIN', color: '#00FFB3' },
  { id: 'kit-5', name: 'Patient Selection', shortName: 'PTSEL', color: '#F9E900' },
  { id: 'kit-6', name: 'Safety & Tolerability', shortName: 'SAFE', color: '#FF3CAC' },
  { id: 'kit-7', name: 'Health Economics', shortName: 'HEOR', color: '#FF8C00' },
  { id: 'kit-8', name: 'Emerging Indications', shortName: 'EMERG', color: '#00CED1' },
];

export const KIQS = [
  // Competitive Landscape
  { id: 'kiq-1', kitId: 'kit-1', question: 'How are KOLs comparing LifePearl vs DC Bead in terms of drug loading and clinical outcomes?' },
  { id: 'kiq-2', kitId: 'kit-1', question: 'What new data is being presented on HepaSphere microspheres in HCC?' },
  { id: 'kiq-3', kitId: 'kit-1', question: 'How is the degradable vs permanent microsphere debate evolving?' },
  // Combination Therapy
  { id: 'kiq-4', kitId: 'kit-2', question: 'What new TACE + immunotherapy combination data is being presented (EMERALD-1, LEAP-012)?' },
  { id: 'kiq-5', kitId: 'kit-2', question: 'How are clinicians sequencing TACE with systemic therapies in intermediate HCC?' },
  { id: 'kiq-6', kitId: 'kit-2', question: 'What is the KOL consensus on optimal TACE-IO combination protocols?' },
  // Technical Innovation
  { id: 'kiq-7', kitId: 'kit-3', question: 'What advances in bead technology and drug elution profiles are being discussed?' },
  { id: 'kiq-8', kitId: 'kit-3', question: 'How is CBCT and cone-beam CT guidance improving TACE outcomes?' },
  { id: 'kiq-9', kitId: 'kit-3', question: 'What role do degradable microspheres (BioPearl) play in re-treatment strategies?' },
  // Clinical Outcomes
  { id: 'kiq-10', kitId: 'kit-4', question: 'What objective response rates are being reported for DEB-TACE in intermediate HCC?' },
  { id: 'kiq-11', kitId: 'kit-4', question: 'How do real-world DEB-TACE outcomes compare to clinical trial results?' },
  { id: 'kiq-12', kitId: 'kit-4', question: 'What survival data is emerging from TACE-IO combination trials?' },
  // Patient Selection
  { id: 'kiq-13', kitId: 'kit-5', question: 'How are treatment algorithms evolving for BCLC-B sub-staging?' },
  { id: 'kiq-14', kitId: 'kit-5', question: 'What criteria are KOLs using to select patients for TACE vs systemic therapy?' },
  { id: 'kiq-15', kitId: 'kit-5', question: 'How does liver function (Child-Pugh, ALBI) influence DEB-TACE patient selection?' },
  // Safety & Tolerability
  { id: 'kiq-16', kitId: 'kit-6', question: 'What is the latest data on post-embolization syndrome incidence and management?' },
  { id: 'kiq-17', kitId: 'kit-6', question: 'How do hepatotoxicity profiles compare between different DEB platforms?' },
  { id: 'kiq-18', kitId: 'kit-6', question: 'What safety signals are emerging from TACE-immunotherapy combinations?' },
  // Health Economics
  { id: 'kiq-19', kitId: 'kit-7', question: 'How are European payers evaluating cost-effectiveness of DEB-TACE vs cTACE?' },
  { id: 'kiq-20', kitId: 'kit-7', question: 'What reimbursement changes are anticipated for TACE-IO combinations?' },
  { id: 'kiq-21', kitId: 'kit-7', question: 'How do procedure volumes and hospital economics differ across European markets?' },
  // Emerging Indications
  { id: 'kiq-22', kitId: 'kit-8', question: 'What data supports DEB-TACE in metastatic colorectal cancer (mCRC) liver metastases?' },
  { id: 'kiq-23', kitId: 'kit-8', question: 'Is there emerging evidence for TACE in intrahepatic cholangiocarcinoma (ICC)?' },
  { id: 'kiq-24', kitId: 'kit-8', question: 'What novel indications beyond HCC are generating clinical interest?' },
];

export const PRODUCTS = [
  { id: 'prod-1', name: 'LifePearl', company: 'Terumo', molecule: 'PEG microspheres (100-300/200-400\u00B5m)', type: 'own', color: '#00A8FF' },
  { id: 'prod-2', name: 'BioPearl', company: 'Terumo', molecule: 'Degradable PEG microspheres', type: 'own', color: '#00FFB3' },
  { id: 'prod-3', name: 'DC Bead', company: 'Boston Scientific', molecule: 'PVA microspheres', type: 'competitor', color: '#FF3366' },
  { id: 'prod-4', name: 'DC Bead LUMI', company: 'Boston Scientific', molecule: 'Radiopaque PVA microspheres', type: 'competitor', color: '#FF8C00' },
  { id: 'prod-5', name: 'HepaSphere', company: 'Merit Medical', molecule: 'Expandable co-polymer microspheres', type: 'competitor', color: '#F9E900' },
];

export const TRIALS = [
  { id: 'trial-1', name: 'EMERALD-1', product: 'prod-1', description: 'DEB-TACE + durvalumab \u00B1 bevacizumab vs DEB-TACE alone in intermediate HCC', phase: 'Phase 3' },
  { id: 'trial-2', name: 'LEAP-012', product: 'prod-1', description: 'TACE + lenvatinib + pembrolizumab vs TACE alone in intermediate HCC', phase: 'Phase 3' },
  { id: 'trial-3', name: 'COLLISION', product: 'prod-1', description: 'Thermal ablation vs surgical resection in colorectal liver metastases', phase: 'Phase 3' },
  { id: 'trial-4', name: 'BIOPEARL-ONE', product: 'prod-2', description: 'Safety and efficacy of degradable BioPearl microspheres in HCC', phase: 'Phase 2' },
  { id: 'trial-5', name: 'TACE-3', product: 'prod-3', description: 'DEB-TACE vs bland embolization in HCC', phase: 'Phase 3' },
  { id: 'trial-6', name: 'CheckMate 74W', product: 'prod-1', description: 'Nivolumab + ipilimumab + TACE vs TACE alone in intermediate HCC', phase: 'Phase 3' },
  { id: 'trial-7', name: 'TALENTACE', product: 'prod-1', description: 'Talimogene + TACE combination in HCC', phase: 'Phase 2' },
  { id: 'trial-8', name: 'ORIENT-32', product: 'prod-1', description: 'Sintilimab + bevacizumab biosimilar in unresectable HCC', phase: 'Phase 3' },
];

export const DISCUSSION_CONTEXTS = [
  { id: 'ctx-1', name: 'Oral Session', icon: 'Presentation' },
  { id: 'ctx-2', name: 'Poster Discussion', icon: 'FileText' },
  { id: 'ctx-3', name: 'Advisory Board', icon: 'Users' },
  { id: 'ctx-4', name: 'Satellite Symposium', icon: 'Radio' },
  { id: 'ctx-5', name: 'Hallway Conversation', icon: 'MessageCircle' },
  { id: 'ctx-6', name: 'Social Event', icon: 'Wine' },
  { id: 'ctx-7', name: 'Exhibition Booth', icon: 'Store' },
];

export const TEAM_MEMBERS = [
  { id: 'user-1', name: 'Dr. Maria Santos', role: 'Field Clinical Specialist Lead', initials: 'MS', color: '#00A8FF', streak: 3, totalInsights: 9, points: 158, isCurrentUser: true },
  { id: 'user-2', name: 'Dr. Thomas Richter', role: 'Senior Field Clinical Specialist', initials: 'TR', color: '#9D4EDD', streak: 3, totalInsights: 7, points: 134 },
  { id: 'user-3', name: 'Dr. Sophie Laurent', role: 'MSL \u2014 Interventional Oncology', initials: 'SL', color: '#00FFB3', streak: 2, totalInsights: 6, points: 102 },
  { id: 'user-4', name: 'Dr. Alessandro Conti', role: 'Medical Director, IO', initials: 'AC', color: '#FF3CAC', streak: 3, totalInsights: 5, points: 110 },
  { id: 'user-5', name: 'Dr. Elena Petrova', role: 'Field Clinical Specialist', initials: 'EP', color: '#F9E900', streak: 1, totalInsights: 4, points: 68 },
  { id: 'user-6', name: 'Dr. Henrik Andersen', role: 'Clinical Application Specialist', initials: 'HA', color: '#FF8C00', streak: 2, totalInsights: 3, points: 57 },
];

export const SENTIMENTS = [
  { id: 'positive', label: 'Positive', color: '#00FFB3' },
  { id: 'neutral', label: 'Neutral', color: '#F9E900' },
  { id: 'negative', label: 'Negative', color: '#FF3366' },
  { id: 'mixed', label: 'Mixed', color: '#FF8C00' },
];

export const MOCK_INSIGHTS = [
  {
    id: 'ins-1',
    authorId: 'user-1',
    timestamp: '2025-09-15T09:15:00Z',
    day: 3,
    kitId: 'kit-2',
    kiqId: 'kiq-4',
    contextId: 'ctx-1',
    sessionTitle: 'Late-Breaking: EMERALD-1 Updated Overall Survival Analysis',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1'],
    sentiment: 'positive',
    narrative: 'EMERALD-1 updated OS data presented by Prof. Lencioni. DEB-TACE + durvalumab + bevacizumab showed median OS of 22.7 months vs 15.8 months for DEB-TACE alone (HR 0.72, p=0.008). Prof. Vogl in the audience noted this is "the first Phase 3 to validate TACE-IO combination in intermediate HCC." Strong interest in the LifePearl DEB protocol used. Q&A focused on optimal timing of TACE relative to immunotherapy dosing.',
    tags: ['EMERALD-1', 'late-breaking', 'TACE-IO-combination'],
    likes: ['user-2', 'user-3', 'user-4', 'user-5'],
    comments: [
      { id: 'c-1', authorId: 'user-2', text: 'This validates our TACE-IO combination strategy. Should we prepare updated clinical evidence summaries?', timestamp: '2025-09-15T09:30:00Z' },
      { id: 'c-2', authorId: 'user-4', text: 'The LifePearl protocol detail is key \u2014 confirms our DEB is the platform of choice for combination approaches.', timestamp: '2025-09-15T09:45:00Z' },
    ],
    isHot: true,
    linkedSocialPosts: ['social-1'],
  },
  {
    id: 'ins-2',
    authorId: 'user-2',
    timestamp: '2025-09-15T10:30:00Z',
    day: 3,
    kitId: 'kit-1',
    kiqId: 'kiq-1',
    contextId: 'ctx-1',
    sessionTitle: 'DEB-TACE Bead Comparison: Head-to-Head Clinical Data',
    track: 'track-3',
    products: ['prod-1', 'prod-3', 'prod-5'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Multi-center retrospective study (N=312) comparing LifePearl, DC Bead, and HepaSphere in intermediate HCC. LifePearl showed significantly longer drug elution time in ex-vivo testing (sustained release over 14 days vs 7 days for DC Bead). Objective response rate at 6 months: LifePearl 72%, DC Bead 65%, HepaSphere 58%. Prof. Bargellini noted the PEG-based microspheres have "more predictable behavior" than PVA-based platforms. Several interventional radiologists asked about re-treatment protocols.',
    tags: ['head-to-head', 'bead-comparison', 'drug-elution'],
    likes: ['user-1', 'user-3', 'user-6'],
    comments: [
      { id: 'c-3', authorId: 'user-1', text: 'The sustained drug elution data is powerful. We need this in our evidence package for procurement discussions.', timestamp: '2025-09-15T10:45:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: ['social-2'],
  },
  {
    id: 'ins-3',
    authorId: 'user-3',
    timestamp: '2025-09-15T11:00:00Z',
    day: 3,
    kitId: 'kit-3',
    kiqId: 'kiq-9',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: BioPearl Degradable Microsphere 12-Month Safety Data',
    track: 'track-3',
    products: ['prod-2'],
    trials: ['trial-4'],
    sentiment: 'positive',
    narrative: 'BIOPEARL-ONE 12-month follow-up poster showed complete bead degradation in 85% of patients by 6 months on MRI. Re-treatment with fresh LifePearl was successful in all cases with no vascular occlusion issues. Grade 3+ AE rate was only 4.2%, comparable to permanent DEBs. Prof. Veloso Gomes presented and emphasized that degradable beads "open the door to true re-treatment optimization." Heavy poster traffic \u2014 counted 60+ visitors. Multiple KOLs photographing the degradation timeline data.',
    tags: ['BioPearl', 'degradable', 're-treatment', 'safety'],
    likes: ['user-1', 'user-2', 'user-4', 'user-5', 'user-6'],
    comments: [
      { id: 'c-4', authorId: 'user-4', text: 'The re-treatment narrative is exactly what differentiates BioPearl. No competitor has this.', timestamp: '2025-09-15T11:20:00Z' },
      { id: 'c-5', authorId: 'user-1', text: 'Can we get the degradation timeline images for our field presentations? This visual is compelling.', timestamp: '2025-09-15T11:30:00Z' },
    ],
    isHot: true,
    linkedSocialPosts: ['social-3'],
  },
  {
    id: 'ins-4',
    authorId: 'user-4',
    timestamp: '2025-09-15T12:15:00Z',
    day: 3,
    kitId: 'kit-5',
    kiqId: 'kiq-13',
    contextId: 'ctx-4',
    sessionTitle: 'Satellite: Refining BCLC-B \u2014 Who Benefits Most from TACE?',
    track: 'track-1',
    products: [],
    trials: [],
    sentiment: 'positive',
    narrative: 'Expert panel discussed BCLC-B sub-staging at Terumo-sponsored satellite. Strong consensus that BCLC-B is too heterogeneous \u2014 patients range from "ideal TACE candidates" to "better served by systemic therapy." Prof. Forner proposed a 3-tier sub-classification: B1 (well-defined, <5 lesions), B2 (diffuse but contained), B3 (extensive/infiltrative). Panel agreed B1 patients are "perfect for DEB-TACE" while B3 should go directly to systemic. B2 is where TACE-IO combinations shine. Audience poll: 74% support sub-staging.',
    tags: ['BCLC-staging', 'patient-selection', 'sub-classification'],
    likes: ['user-1', 'user-2'],
    comments: [
      { id: 'c-6', authorId: 'user-1', text: 'The B1/B2/B3 framework could reshape treatment algorithms in our favor. More TACE-eligible patients identified.', timestamp: '2025-09-15T12:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-5',
    authorId: 'user-1',
    timestamp: '2025-09-15T14:00:00Z',
    day: 3,
    kitId: 'kit-6',
    kiqId: 'kiq-16',
    contextId: 'ctx-5',
    sessionTitle: 'Hallway Discussion with Prof. Vogl on Post-Embolization Syndrome',
    track: 'track-1',
    products: ['prod-1', 'prod-3'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Extended conversation with Prof. Vogl after the morning sessions. He shared preliminary data from his Frankfurt cohort showing post-embolization syndrome (PES) rates of 38% with LifePearl vs 52% with DC Bead (p=0.03). He attributes the difference to LifePearl\'s softer, more compressible microsphere structure and predictable sizing. Mentioned he\'s writing a comparative review on bead characteristics and patient comfort. Offered to present at our next advisory board. Very productive engagement.',
    tags: ['PES', 'safety', 'KOL-engagement', 'bead-comparison'],
    likes: ['user-2', 'user-3', 'user-4'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-6',
    authorId: 'user-5',
    timestamp: '2025-09-15T14:30:00Z',
    day: 3,
    kitId: 'kit-7',
    kiqId: 'kiq-19',
    contextId: 'ctx-4',
    sessionTitle: 'HEOR Session: Cost-Effectiveness of DEB-TACE in European Healthcare Systems',
    track: 'track-1',
    products: ['prod-1', 'prod-3'],
    trials: [],
    sentiment: 'mixed',
    narrative: 'HEOR session focused on DEB-TACE economics. German GBA representative indicated DEB reimbursement review is ongoing. UK NICE representative noted DEB-TACE has "strong cost-effectiveness vs cTACE when re-treatment rates are factored in." French payer expressed concerns about upfront bead costs vs conventional lipiodol TACE. Key insight: re-treatment reduction and shorter hospital stays are the strongest economic arguments. Italian data showed DEB-TACE reduced average procedures per patient from 4.2 to 2.8 vs cTACE.',
    tags: ['HEOR', 'reimbursement', 'cost-effectiveness'],
    likes: ['user-4'],
    comments: [
      { id: 'c-7', authorId: 'user-4', text: 'The Italian re-treatment data is gold for our market access teams. Fewer procedures = lower total cost of care.', timestamp: '2025-09-15T15:00:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-7',
    authorId: 'user-6',
    timestamp: '2025-09-15T15:30:00Z',
    day: 3,
    kitId: 'kit-1',
    kiqId: 'kiq-2',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: DC Bead LUMI Radiopaque Outcomes in HCC',
    track: 'track-3',
    products: ['prod-4'],
    trials: [],
    sentiment: 'neutral',
    narrative: 'Boston Scientific presented DC Bead LUMI (radiopaque bead) data in HCC (N=89). Real-time visualization during delivery is appealing to interventional radiologists \u2014 92% rated visibility as "excellent." However, objective response rates at 6 months were comparable to standard DC Bead (63% vs 65%), not a clinical improvement. Drug loading capacity is slightly lower than standard DC Bead. Several KOLs questioned whether visibility alone justifies the premium pricing. Prof. Maleux commented that CBCT with standard beads achieves similar procedural confidence.',
    tags: ['DC-Bead-LUMI', 'radiopaque', 'competitor-data'],
    likes: ['user-1', 'user-2'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-5'],
  },
  {
    id: 'ins-8',
    authorId: 'user-2',
    timestamp: '2025-09-15T16:00:00Z',
    day: 3,
    kitId: 'kit-4',
    kiqId: 'kiq-11',
    contextId: 'ctx-1',
    sessionTitle: 'Symposium: Real-World DEB-TACE Outcomes \u2014 European Registry Data',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Large European registry (TACE Registry Europe, N=1,847) presented 5-year outcomes. Median OS for DEB-TACE in BCLC-B was 26.3 months. Centers using LifePearl had slightly higher ORR (68% vs 62% pooled) but the difference was not statistically significant after adjustment. Key finding: centers performing >50 TACE procedures/year had 35% better outcomes than low-volume centers, regardless of bead choice. Prof. Pereira called for "centralization of complex IO procedures." Strong argument for center-of-excellence model.',
    tags: ['real-world', 'registry', 'center-volume'],
    likes: ['user-1', 'user-3'],
    comments: [
      { id: 'c-8', authorId: 'user-3', text: 'The volume-outcome relationship supports our training and proctoring programs. Higher volume = better outcomes.', timestamp: '2025-09-15T16:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-9',
    authorId: 'user-3',
    timestamp: '2025-09-15T17:00:00Z',
    day: 3,
    kitId: 'kit-8',
    kiqId: 'kiq-22',
    contextId: 'ctx-7',
    sessionTitle: 'Exhibition Booth Discussion \u2014 DEB-TACE in Colorectal Liver Metastases',
    track: 'track-4',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Met researchers from Barcelona Hospital Cl\u00EDnic at the exhibition presenting their series on LifePearl-loaded irinotecan for colorectal liver metastases (N=45). Disease control rate at 3 months was 78%. They used 100-300\u00B5m LifePearl loaded with irinotecan 100mg. Importantly, all patients had failed at least 2 lines of systemic therapy. The PI mentioned they\'re planning a prospective multicenter trial for 2026. Exchanged contact information for potential collaboration.',
    tags: ['mCRC', 'irinotecan', 'emerging-indication'],
    likes: ['user-1', 'user-4', 'user-6'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-10',
    authorId: 'user-1',
    timestamp: '2025-09-14T09:30:00Z',
    day: 2,
    kitId: 'kit-2',
    kiqId: 'kiq-5',
    contextId: 'ctx-1',
    sessionTitle: 'Opening Plenary: The TACE-Immunotherapy Revolution',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1', 'trial-2'],
    sentiment: 'positive',
    narrative: 'Congress opened with Prof. Llovet presenting the rationale for TACE-IO combinations. TACE induces immunogenic cell death, releasing tumor antigens that synergize with checkpoint inhibitors. EMERALD-1 and LEAP-012 are "validating a decade of preclinical hypothesis." He emphasized that DEB-TACE is preferred over cTACE in combination trials due to more predictable embolization and standardized protocols. Estimated 3,000+ attendees in the main hall. Standing ovation at the end.',
    tags: ['opening-plenary', 'TACE-IO', 'immunogenic-cell-death'],
    likes: ['user-2', 'user-3', 'user-4', 'user-5', 'user-6'],
    comments: [
      { id: 'c-9', authorId: 'user-2', text: 'The DEB-TACE preference in combination trials is a huge talking point. We should amplify this.', timestamp: '2025-09-14T10:00:00Z' },
      { id: 'c-10', authorId: 'user-4', text: 'Immunogenic cell death mechanism plays right into our LifePearl positioning.', timestamp: '2025-09-14T10:15:00Z' },
    ],
    isHot: true,
    linkedSocialPosts: ['social-6'],
  },
  {
    id: 'ins-11',
    authorId: 'user-2',
    timestamp: '2025-09-14T11:00:00Z',
    day: 2,
    kitId: 'kit-3',
    kiqId: 'kiq-7',
    contextId: 'ctx-1',
    sessionTitle: 'Technical Session: Next-Generation Microsphere Design',
    track: 'track-3',
    products: ['prod-1', 'prod-2'],
    trials: ['trial-4'],
    sentiment: 'positive',
    narrative: 'Session on microsphere technology evolution. LifePearl\'s PEG-based chemistry was highlighted for superior compressibility (passes through smaller microcatheters), consistent sizing (CV < 5%), and extended suspension time (357 seconds vs 204 for DC Bead). BioPearl degradation mechanism presented \u2014 controlled hydrolysis over 3-6 months. KOLs particularly interested in the re-treatment implications. Prof. Helmberger noted that degradable beads "could change the entire TACE paradigm from palliative to curative-intent repeated treatments."',
    tags: ['microsphere-technology', 'PEG-chemistry', 'BioPearl'],
    likes: ['user-1', 'user-3'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-7'],
  },
  {
    id: 'ins-12',
    authorId: 'user-4',
    timestamp: '2025-09-14T12:30:00Z',
    day: 2,
    kitId: 'kit-5',
    kiqId: 'kiq-14',
    contextId: 'ctx-3',
    sessionTitle: 'Advisory Board: Treatment Algorithms for Intermediate HCC',
    track: 'track-1',
    products: [],
    trials: [],
    sentiment: 'positive',
    narrative: 'Participated in closed advisory board with 10 European interventional oncologists. Unanimous agreement that BCLC-B needs refinement. Key debate: when to start with TACE vs go directly to systemic in the "gray zone" patients. Group endorsed a "TACE-first with early evaluation" strategy \u2014 perform 1-2 DEB-TACE cycles, assess response at 3 months, then decide on continuation vs systemic switch. Prof. Bargellini\'s proposal for a standardized response assessment protocol was well-received. Terumo seen as a thought leader in treatment standardization.',
    tags: ['advisory-board', 'treatment-algorithm', 'TACE-first'],
    likes: ['user-1', 'user-2', 'user-3'],
    comments: [
      { id: 'c-11', authorId: 'user-1', text: 'The TACE-first strategy with early assessment is very aligned with our messaging. Great strategic intel.', timestamp: '2025-09-14T13:00:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-13',
    authorId: 'user-6',
    timestamp: '2025-09-14T14:00:00Z',
    day: 2,
    kitId: 'kit-6',
    kiqId: 'kiq-17',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: Hepatotoxicity Comparison Across DEB Platforms',
    track: 'track-1',
    products: ['prod-1', 'prod-3', 'prod-5'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Important safety poster from Italian multi-center group comparing hepatotoxicity across DEB platforms (N=234). Grade 3+ liver toxicity: LifePearl 3.8%, DC Bead 6.2%, HepaSphere 8.7%. The difference between LifePearl and HepaSphere was statistically significant (p=0.02). Authors attributed the finding to LifePearl\'s more controlled drug elution profile \u2014 less initial burst release. Several attendees questioned whether the HepaSphere expandability might cause more parenchymal damage. Clinically relevant for safety-conscious operators.',
    tags: ['hepatotoxicity', 'safety-comparison', 'drug-elution'],
    likes: ['user-1', 'user-5'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-14',
    authorId: 'user-5',
    timestamp: '2025-09-14T15:00:00Z',
    day: 2,
    kitId: 'kit-4',
    kiqId: 'kiq-10',
    contextId: 'ctx-4',
    sessionTitle: 'Satellite: Optimizing DEB-TACE Outcomes \u2014 Technique Matters',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Multi-speaker session on DEB-TACE technique optimization. Key messages: 1) Superselective catheterization improves ORR from 55% to 74%, 2) Smaller beads (100-300\u00B5m) achieve better tumor penetration than larger sizes, 3) CBCT-guided DEB-TACE reduces non-target embolization by 40%. Prof. Kloeckner presented data showing that standardized LifePearl loading protocol (37.5mg/mL doxorubicin, 1-hour loading time) achieves more consistent drug delivery than ad-hoc protocols. Strong argument for protocolized approach.',
    tags: ['technique-optimization', 'superselective', 'CBCT-guidance'],
    likes: ['user-2'],
    comments: [
      { id: 'c-12', authorId: 'user-2', text: 'The standardized loading protocol data supports our proctoring program. We should formalize a best-practice guide.', timestamp: '2025-09-14T15:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-15',
    authorId: 'user-3',
    timestamp: '2025-09-14T16:30:00Z',
    day: 2,
    kitId: 'kit-1',
    kiqId: 'kiq-3',
    contextId: 'ctx-7',
    sessionTitle: 'Exhibition: Boston Scientific Booth \u2014 DC Bead Franchise Review',
    track: 'track-4',
    products: ['prod-3', 'prod-4'],
    trials: [],
    sentiment: 'neutral',
    narrative: 'Visited the Boston Scientific exhibition booth. Heavy promotion of DC Bead LUMI as the "next evolution in TACE." Booth staff emphasized radiopacity as a differentiator but couldn\'t provide head-to-head outcome data vs standard DC Bead or LifePearl. Collected their updated IFU and promotional materials. Notably, several KOLs at the booth were skeptical about the LUMI premium. Prof. Maleux told a Boston rep: "I can see the beads fine on CBCT \u2014 why do I need radiopaque beads?" DC Bead market share appears stable but not growing.',
    tags: ['DC-Bead', 'LUMI', 'competitor-intelligence'],
    likes: ['user-1', 'user-4'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-8'],
  },
  {
    id: 'ins-16',
    authorId: 'user-1',
    timestamp: '2025-09-14T17:30:00Z',
    day: 2,
    kitId: 'kit-2',
    kiqId: 'kiq-6',
    contextId: 'ctx-6',
    sessionTitle: 'Evening Reception \u2014 TACE-IO Combination Protocol Discussions',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1', 'trial-2', 'trial-6'],
    sentiment: 'positive',
    narrative: 'At the welcome reception, had extended conversation with Prof. Lencioni about optimal TACE-IO sequencing. He believes DEB-TACE should precede immunotherapy by 2-3 weeks to maximize antigen release before checkpoint inhibitor dosing. Also discussed CheckMate 74W (nivo+ipi+TACE) \u2014 he expects results in 2026 and predicts it will confirm the TACE-IO paradigm. He mentioned that LifePearl is his "go-to DEB" because of consistent sizing and predictable drug release. Very useful competitive framing and endorsement.',
    tags: ['TACE-IO-sequencing', 'KOL-engagement', 'LifePearl-endorsement'],
    likes: ['user-2', 'user-3', 'user-4', 'user-5', 'user-6'],
    comments: [
      { id: 'c-13', authorId: 'user-4', text: 'A Lencioni endorsement of LifePearl is extremely valuable. Can we get a quote for our materials?', timestamp: '2025-09-14T18:00:00Z' },
      { id: 'c-14', authorId: 'user-2', text: 'The TACE-first sequencing insight is actionable. Worth sharing with HQ for medical strategy.', timestamp: '2025-09-14T18:15:00Z' },
    ],
    isHot: true,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-17',
    authorId: 'user-2',
    timestamp: '2025-09-15T08:00:00Z',
    day: 3,
    kitId: 'kit-8',
    kiqId: 'kiq-23',
    contextId: 'ctx-1',
    sessionTitle: 'Morning Session: TACE Beyond HCC \u2014 Expanding the Horizon',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Session on emerging TACE indications beyond HCC. Intrahepatic cholangiocarcinoma (ICC) data from French multicenter group (N=67): DEB-TACE with LifePearl achieved disease control rate of 64% at 6 months in patients ineligible for surgery or systemic therapy. mCRC liver metastases showed promise with irinotecan-loaded beads. A Korean group presented early data on TACE in neuroendocrine liver metastases with 82% symptom improvement. Prof. Raoul called ICC "the next frontier for DEB-TACE." The field is clearly expanding beyond HCC.',
    tags: ['ICC', 'mCRC', 'neuroendocrine', 'emerging-indications'],
    likes: ['user-3', 'user-5'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-18',
    authorId: 'user-6',
    timestamp: '2025-09-15T08:45:00Z',
    day: 3,
    kitId: 'kit-7',
    kiqId: 'kiq-21',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: Procedure Volume Trends and Economic Impact Across Europe',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'HEOR poster from pan-European survey (18 countries, 245 centers). DEB-TACE procedure volumes grew 12% year-over-year in 2024. Germany, France, and Italy account for 58% of European DEB-TACE volume. Shift from cTACE to DEB-TACE accelerating \u2014 DEB now represents 67% of all TACE procedures in high-volume centers (vs 45% in 2020). Average cost per DEB-TACE session: \u20AC4,200 vs \u20AC2,800 for cTACE, but total treatment cost is lower due to fewer re-treatments. Strong economic argument for DEB adoption.',
    tags: ['procedure-volumes', 'DEB-adoption', 'economic-analysis'],
    likes: ['user-1', 'user-4', 'user-5'],
    comments: [
      { id: 'c-15', authorId: 'user-4', text: 'The DEB market share growth from 45% to 67% is a powerful trend. Reinforces our market position.', timestamp: '2025-09-15T09:00:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-19',
    authorId: 'user-4',
    timestamp: '2025-09-14T10:30:00Z',
    day: 2,
    kitId: 'kit-6',
    kiqId: 'kiq-18',
    contextId: 'ctx-1',
    sessionTitle: 'Safety Update: TACE-Immunotherapy Combination Adverse Events',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1', 'trial-2'],
    sentiment: 'positive',
    narrative: 'Pooled safety analysis from EMERALD-1 and LEAP-012 TACE-IO arms. Grade 3+ hepatic AEs: 18% (vs 12% for TACE alone). Most were transient ALT/AST elevations resolving within 4 weeks. No increase in liver-related mortality. Immune-mediated hepatitis occurred in 4.2% of TACE+ICI patients. Key message: TACE-IO combinations are manageable with proper monitoring. Prof. Sangro recommended liver function monitoring every 2 weeks for the first 3 cycles. Reassuring data for the field.',
    tags: ['TACE-IO-safety', 'hepatic-AEs', 'immune-mediated'],
    likes: ['user-1', 'user-2', 'user-3'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-10'],
  },
  {
    id: 'ins-20',
    authorId: 'user-3',
    timestamp: '2025-09-15T13:00:00Z',
    day: 3,
    kitId: 'kit-4',
    kiqId: 'kiq-12',
    contextId: 'ctx-5',
    sessionTitle: 'Hallway Discussion on LEAP-012 Preliminary Signals',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-2'],
    sentiment: 'positive',
    narrative: 'Joined a corridor conversation between three European IO specialists about LEAP-012 interim analysis rumors. All three had heard from investigators that the TACE + lenvatinib + pembrolizumab arm is showing "very encouraging PFS signals" \u2014 potentially 14+ months vs 8 months for TACE alone. If confirmed, this would be the second Phase 3 validating TACE-IO combinations after EMERALD-1. One investigator from Madrid said "DEB-TACE is becoming the backbone of combination approaches in intermediate HCC." LifePearl well-positioned as the platform of choice.',
    tags: ['LEAP-012', 'PFS-signals', 'TACE-backbone'],
    likes: ['user-1', 'user-2', 'user-4'],
    comments: [
      { id: 'c-16', authorId: 'user-1', text: 'If LEAP-012 confirms, it is a paradigm shift. Two positive Phase 3s for TACE-IO would be unprecedented.', timestamp: '2025-09-15T13:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-21',
    authorId: 'user-5',
    timestamp: '2025-09-14T13:00:00Z',
    day: 2,
    kitId: 'kit-8',
    kiqId: 'kiq-24',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: DEB-TACE in NASH/MASH-Related HCC',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'neutral',
    narrative: 'German group presented outcomes of DEB-TACE in NASH/MASH-related HCC (N=78) vs viral hepatitis HCC (N=156). NASH-HCC patients had larger tumors at diagnosis (mean 5.2cm vs 3.8cm) and were more often BCLC-B. ORR was comparable (65% vs 68%) but NASH patients had higher rates of post-embolization liver decompensation (8.2% vs 3.4%). Authors recommended more conservative loading doses in NASH patients with underlying steatotic liver disease. Growing patient population \u2014 NASH-HCC now accounts for 25% of new HCC diagnoses in Western Europe.',
    tags: ['NASH-HCC', 'steatotic-liver', 'patient-population'],
    likes: ['user-1', 'user-2', 'user-4'],
    comments: [
      { id: 'c-17', authorId: 'user-4', text: 'NASH-HCC is a rapidly growing segment. We need TACE protocols specifically optimized for these patients.', timestamp: '2025-09-14T13:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-22',
    authorId: 'user-1',
    timestamp: '2025-09-15T17:00:00Z',
    day: 3,
    kitId: 'kit-3',
    kiqId: 'kiq-8',
    contextId: 'ctx-1',
    sessionTitle: 'Late Afternoon: CBCT Guidance \u2014 The New Standard for DEB-TACE',
    track: 'track-4',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Session on imaging guidance for TACE. Consensus is shifting toward CBCT as standard-of-care for DEB-TACE guidance. Data from 8 European centers (N=567) showed CBCT-guided DEB-TACE improved complete response rate from 42% to 61% (p<0.001). Non-target embolization dropped from 8.3% to 2.1%. Prof. Vogl presented his "3D tumor mapping" technique using CBCT to plan bead deposition. Key message: CBCT + standardized DEB protocol = reproducible, high-quality outcomes. This supports our training and education investments.',
    tags: ['CBCT', 'imaging-guidance', 'technique-standardization'],
    likes: ['user-2', 'user-3'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-12'],
  },
  {
    id: 'ins-23',
    authorId: 'user-2',
    timestamp: '2025-09-14T17:00:00Z',
    day: 2,
    kitId: 'kit-7',
    kiqId: 'kiq-20',
    contextId: 'ctx-3',
    sessionTitle: 'Advisory Board: Reimbursement Landscape for TACE-IO Combinations',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1'],
    sentiment: 'mixed',
    narrative: 'Closed payer advisory board with representatives from 5 EU markets. Key takeaway: Germany and UK most likely to reimburse TACE-IO combinations first, driven by EMERALD-1 data. France and Spain require additional cost-effectiveness evidence. All agreed that the combined cost of TACE + immunotherapy is a challenge (estimated \u20AC80,000-120,000/patient/year). Suggestion: Terumo should collaborate with pharma partners to develop joint value dossiers. The DEB component cost is small relative to ICI drugs \u2014 "TACE adds value, not cost" framing resonated with payers.',
    tags: ['payer-advisory', 'TACE-IO-reimbursement', 'value-framing'],
    likes: ['user-1', 'user-4'],
    comments: [
      { id: 'c-18', authorId: 'user-4', text: 'The "TACE adds value not cost" framing is perfect. DEB is <5% of total combo cost but enables the IO mechanism.', timestamp: '2025-09-14T17:30:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-24',
    authorId: 'user-6',
    timestamp: '2025-09-14T11:30:00Z',
    day: 2,
    kitId: 'kit-4',
    kiqId: 'kiq-10',
    contextId: 'ctx-5',
    sessionTitle: 'Hallway: Response Assessment Discussion with Italian Investigators',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Spoke with two Italian interventional oncologists about response assessment after DEB-TACE. Both prefer mRECIST over RECIST 1.1 for evaluating TACE response, as mRECIST better captures tumor necrosis. They reported ORR of 70-75% with LifePearl using mRECIST vs 45-50% using RECIST 1.1 in the same cohort. Both mentioned they assess at 4-6 weeks post-TACE rather than 3 months, allowing earlier decisions on re-treatment. Real behavioral change: mRECIST adoption in TACE assessment is now >80% in Italian IO centers.',
    tags: ['mRECIST', 'response-assessment', 'treatment-decisions'],
    likes: ['user-1', 'user-2', 'user-4'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
  {
    id: 'ins-25',
    authorId: 'user-1',
    timestamp: '2025-09-15T18:00:00Z',
    day: 3,
    kitId: 'kit-1',
    kiqId: 'kiq-1',
    contextId: 'ctx-6',
    sessionTitle: 'Day 3 Evening: Competitive Positioning Debrief',
    track: 'track-1',
    products: ['prod-1', 'prod-2', 'prod-3', 'prod-4'],
    trials: ['trial-1', 'trial-4'],
    sentiment: 'positive',
    narrative: 'End of Day 3 team debrief. Competitive landscape summary: 1) LifePearl is the platform of choice for TACE-IO combination trials (EMERALD-1, LEAP-012) \u2014 no competitor has this positioning, 2) BioPearl re-treatment narrative is unique and resonating strongly, 3) DC Bead LUMI visibility advantage is being questioned by KOLs who use CBCT, 4) HepaSphere safety profile is weakest in comparative data. Key strategic priority: position LifePearl as "the evidence-based DEB for the combination era." BioPearl as "the future of TACE re-treatment." Recommend updating our congress deck tonight.',
    tags: ['competitive-debrief', 'strategic-positioning', 'team-alignment'],
    likes: ['user-2', 'user-3', 'user-4', 'user-5', 'user-6'],
    comments: [
      { id: 'c-19', authorId: 'user-4', text: 'Perfect framing: LifePearl for combinations, BioPearl for re-treatment. Two distinct value propositions.', timestamp: '2025-09-15T18:15:00Z' },
      { id: 'c-20', authorId: 'user-2', text: 'The EMERALD-1 OS data from this morning seals it. LifePearl IS the combination-era DEB.', timestamp: '2025-09-15T18:30:00Z' },
    ],
    isHot: true,
    linkedSocialPosts: ['social-15'],
  },
  {
    id: 'ins-26',
    authorId: 'user-3',
    timestamp: '2025-09-15T11:30:00Z',
    day: 3,
    kitId: 'kit-5',
    kiqId: 'kiq-15',
    contextId: 'ctx-1',
    sessionTitle: 'Debate: Liver Function and DEB-TACE \u2014 When is it Too Late?',
    track: 'track-1',
    products: ['prod-1'],
    trials: [],
    sentiment: 'mixed',
    narrative: 'Lively debate session on liver function thresholds for DEB-TACE. Prof. Bolondi (pro-conservative) vs Prof. Kudo (pro-aggressive). Audience poll: 72% support treating Child-Pugh B7 patients selectively. ALBI score gaining traction as a more granular assessment tool. Bolondi argued that treating Child-Pugh B8+ patients with TACE "does more harm than good." Kudo countered with Japanese data showing acceptable outcomes in selected B7 patients with superselective technique. Compromise: ALBI grade 1-2 = proceed, ALBI grade 3 = systemic therapy preferred.',
    tags: ['liver-function', 'Child-Pugh', 'ALBI-score', 'patient-selection'],
    likes: ['user-1', 'user-4'],
    comments: [],
    isHot: false,
    linkedSocialPosts: ['social-14'],
  },
  {
    id: 'ins-27',
    authorId: 'user-4',
    timestamp: '2025-09-15T16:30:00Z',
    day: 3,
    kitId: 'kit-2',
    kiqId: 'kiq-4',
    contextId: 'ctx-4',
    sessionTitle: 'Satellite: TACE-IO Combination \u2014 The Evidence and the Promise',
    track: 'track-1',
    products: ['prod-1'],
    trials: ['trial-1', 'trial-2', 'trial-6'],
    sentiment: 'positive',
    narrative: 'Terumo-sponsored satellite symposium on TACE-IO combinations. Prof. Lencioni presented EMERALD-1 deep-dive showing benefit across all BCLC-B sub-groups. Prof. Forner reviewed LEAP-012 design and rationale. Key highlight: pooled analysis suggests TACE-IO combinations could extend median OS from ~16 months to 22-24 months in intermediate HCC \u2014 a 40% improvement. Prof. Bargellini presented the technical case for DEB-TACE over cTACE in combinations (standardized, reproducible, predictable). Room was packed \u2014 had to bring in extra chairs. Clear excitement in the IO community.',
    tags: ['TACE-IO', 'satellite', 'OS-improvement', 'DEB-superiority'],
    likes: ['user-1', 'user-2', 'user-3', 'user-5', 'user-6'],
    comments: [
      { id: 'c-21', authorId: 'user-1', text: 'The 40% OS improvement number is a powerful headline. Adding to our key messages for Day 4-5.', timestamp: '2025-09-15T17:00:00Z' },
    ],
    isHot: false,
    linkedSocialPosts: ['social-13'],
  },
  {
    id: 'ins-28',
    authorId: 'user-5',
    timestamp: '2025-09-15T15:00:00Z',
    day: 3,
    kitId: 'kit-3',
    kiqId: 'kiq-7',
    contextId: 'ctx-2',
    sessionTitle: 'Poster: Drug Loading Optimization Across DEB Platforms',
    track: 'track-3',
    products: ['prod-1', 'prod-3', 'prod-5'],
    trials: [],
    sentiment: 'positive',
    narrative: 'Comprehensive ex-vivo study comparing drug loading characteristics. LifePearl: doxorubicin loading 37.5mg/mL, complete loading in 60 min, sustained release over 14 days. DC Bead: max loading 37.5mg/mL but optimal at 25mg/mL, loading time 120 min, burst release pattern. HepaSphere: variable loading due to expansion, less predictable drug elution. Presenter emphasized that LifePearl\'s "load and go" simplicity reduces preparation time by 50% vs DC Bead. Multiple operators asked about standardized loading protocols.',
    tags: ['drug-loading', 'preparation-time', 'elution-profile'],
    likes: ['user-1', 'user-6'],
    comments: [],
    isHot: false,
    linkedSocialPosts: [],
  },
];

export const MOCK_SOCIAL_POSTS = [
  {
    id: 'social-1',
    platform: 'twitter',
    author: 'Prof. Ricardo Defined @RicardoIO_MD',
    handle: '@RicardoIO_MD',
    verified: true,
    timestamp: '2025-09-15T09:20:00Z',
    day: 3,
    content: 'BREAKING: EMERALD-1 updated OS shows DEB-TACE + durvalumab + bevacizumab extends survival to 22.7 months vs 15.8 months. HR 0.72. This changes intermediate HCC management. #CIRSE2025 #TACE #HCC',
    likes: 892,
    retweets: 356,
    hashtags: ['#CIRSE2025', '#TACE', '#HCC'],
    products: ['prod-1'],
    linkedInsightId: 'ins-1',
  },
  {
    id: 'social-2',
    platform: 'twitter',
    author: 'Dr. Clara Hernandez @ClaraIR_BCN',
    handle: '@ClaraIR_BCN',
    verified: true,
    timestamp: '2025-09-15T10:45:00Z',
    day: 3,
    content: 'Head-to-head DEB comparison at #CIRSE2025: LifePearl ORR 72% vs DC Bead 65% vs HepaSphere 58% in intermediate HCC. PEG-based microspheres showing an edge. The sustained drug elution profile matters. #InterventionalOncology',
    likes: 567,
    retweets: 198,
    hashtags: ['#CIRSE2025', '#InterventionalOncology'],
    products: ['prod-1', 'prod-3', 'prod-5'],
    linkedInsightId: 'ins-2',
  },
  {
    id: 'social-3',
    platform: 'linkedin',
    author: 'Dr. Filipe Veloso Gomes',
    handle: 'Filipe Veloso Gomes',
    verified: false,
    timestamp: '2025-09-15T11:15:00Z',
    day: 3,
    content: 'Thrilled to present the BIOPEARL-ONE 12-month data at #CIRSE2025. Complete bead degradation in 85% of patients by 6 months. Successful re-treatment with no vascular occlusion. Degradable microspheres open a new paradigm in TACE \u2014 from palliative to repeated curative-intent treatments. The future of embolization is biodegradable.',
    likes: 234,
    retweets: 78,
    hashtags: ['#CIRSE2025', '#BioPearl', '#Innovation'],
    products: ['prod-2'],
    linkedInsightId: 'ins-3',
  },
  {
    id: 'social-4',
    platform: 'twitter',
    author: 'CIRSE Official @CIRSEsociety',
    handle: '@CIRSEsociety',
    verified: true,
    timestamp: '2025-09-15T12:00:00Z',
    day: 3,
    content: 'Day 3 at #CIRSE2025 is delivering landmark data. EMERALD-1 OS update, BioPearl degradation results, and head-to-head DEB comparisons all presented today. The interventional oncology landscape is evolving rapidly. Full coverage on our website.',
    likes: 1345,
    retweets: 612,
    hashtags: ['#CIRSE2025'],
    products: [],
    linkedInsightId: null,
  },
  {
    id: 'social-5',
    platform: 'twitter',
    author: 'Dr. Andreas Mueller @AndreasIR_Munich',
    handle: '@AndreasIR_Munich',
    verified: true,
    timestamp: '2025-09-15T15:45:00Z',
    day: 3,
    content: 'DC Bead LUMI data at #CIRSE2025: great visibility but ORR comparable to standard DC Bead (63% vs 65%). At a premium price, is radiopacity alone enough? CBCT gives me all the visualization I need with any bead. The value proposition needs work. #TACE',
    likes: 378,
    retweets: 145,
    hashtags: ['#CIRSE2025', '#TACE'],
    products: ['prod-4'],
    linkedInsightId: 'ins-7',
  },
  {
    id: 'social-6',
    platform: 'twitter',
    author: 'EASL Official @EASLnews',
    handle: '@EASLnews',
    verified: true,
    timestamp: '2025-09-14T09:45:00Z',
    day: 2,
    content: 'Standing room only at the #CIRSE2025 opening plenary! Prof. Llovet makes the case for TACE-immunotherapy combinations. "DEB-TACE induces immunogenic cell death \u2014 the perfect partner for checkpoint inhibitors." Over 3,000 attendees. The IO community is energized!',
    likes: 978,
    retweets: 445,
    hashtags: ['#CIRSE2025', '#TACE', '#Immunotherapy'],
    products: ['prod-1'],
    linkedInsightId: 'ins-10',
  },
  {
    id: 'social-7',
    platform: 'twitter',
    author: 'Dr. Yuki Tanaka @YukiIR_Osaka',
    handle: '@YukiIR_Osaka',
    verified: true,
    timestamp: '2025-09-14T11:15:00Z',
    day: 2,
    content: 'Fascinating session on microsphere technology at #CIRSE2025. LifePearl PEG chemistry: suspension time 357s vs DC Bead 204s. Consistent sizing (CV<5%). And now BioPearl with controlled degradation. The science behind the beads matters. #InterventionalOncology',
    likes: 456,
    retweets: 189,
    hashtags: ['#CIRSE2025', '#InterventionalOncology'],
    products: ['prod-1', 'prod-2'],
    linkedInsightId: 'ins-11',
  },
  {
    id: 'social-8',
    platform: 'linkedin',
    author: 'Dr. Marc Van den Berg, PhD',
    handle: 'Marc Van den Berg, PhD',
    verified: false,
    timestamp: '2025-09-14T16:45:00Z',
    day: 2,
    content: 'Visited the Boston Scientific booth at #CIRSE2025. DC Bead LUMI positioning is clear: "See what you deliver." But as Prof. Maleux pointed out, CBCT already provides excellent procedural visualization. The radiopaque premium is a tough sell in cost-conscious European markets. Need stronger clinical outcome data to justify the switch.',
    likes: 167,
    retweets: 42,
    hashtags: ['#CIRSE2025', '#DCBead', '#TACE'],
    products: ['prod-3', 'prod-4'],
    linkedInsightId: 'ins-15',
  },
  {
    id: 'social-9',
    platform: 'twitter',
    author: 'Interventional Oncology SIG @IO_SIG_CIRSE',
    handle: '@IO_SIG_CIRSE',
    verified: true,
    timestamp: '2025-09-14T14:00:00Z',
    day: 2,
    content: 'Safety comparison across DEB platforms at #CIRSE2025. LifePearl shows lowest Grade 3+ hepatotoxicity (3.8% vs 6.2% DC Bead vs 8.7% HepaSphere). Controlled drug elution appears to matter for liver safety. Important data for clinical decision-making.',
    likes: 712,
    retweets: 312,
    hashtags: ['#CIRSE2025', '#DEB', '#Safety'],
    products: ['prod-1', 'prod-3', 'prod-5'],
    linkedInsightId: null,
  },
  {
    id: 'social-10',
    platform: 'twitter',
    author: 'Dr. Sophie Martin @SophieIO_Paris',
    handle: '@SophieIO_Paris',
    verified: true,
    timestamp: '2025-09-14T10:45:00Z',
    day: 2,
    content: 'Reassuring safety data on TACE-immunotherapy combos at #CIRSE2025. Grade 3+ hepatic AEs manageable at 18%. No increase in liver-related mortality. With proper monitoring, TACE-IO combinations are safe and feasible. The combination era is here to stay.',
    likes: 534,
    retweets: 213,
    hashtags: ['#CIRSE2025', '#TACEIO', '#Safety'],
    products: ['prod-1'],
    linkedInsightId: 'ins-19',
  },
  {
    id: 'social-11',
    platform: 'linkedin',
    author: 'Prof. Geert Maleux, MD PhD',
    handle: 'Geert Maleux, MD PhD',
    verified: false,
    timestamp: '2025-09-15T13:30:00Z',
    day: 3,
    content: 'Day 3 at #CIRSE2025: the combination therapy narrative dominates. EMERALD-1 OS update, LEAP-012 signals, CheckMate 74W on the horizon. DEB-TACE is becoming the backbone of intermediate HCC treatment. The question is no longer IF we combine TACE with immunotherapy, but HOW and WHEN.',
    likes: 289,
    retweets: 87,
    hashtags: ['#CIRSE2025', '#TACE', '#Immunotherapy'],
    products: ['prod-1'],
    linkedInsightId: null,
  },
  {
    id: 'social-12',
    platform: 'twitter',
    author: 'IR Techniques @IRTechniques',
    handle: '@IRTechniques',
    verified: true,
    timestamp: '2025-09-15T17:15:00Z',
    day: 3,
    content: 'CBCT-guided DEB-TACE data at #CIRSE2025: complete response up from 42% to 61%. Non-target embolization down from 8.3% to 2.1%. Technique + technology = better outcomes. CBCT should be standard-of-care for every TACE procedure. #InterventionalRadiology',
    likes: 623,
    retweets: 267,
    hashtags: ['#CIRSE2025', '#InterventionalRadiology', '#CBCT'],
    products: ['prod-1'],
    linkedInsightId: 'ins-22',
  },
  {
    id: 'social-13',
    platform: 'twitter',
    author: 'Dr. Elena Garcia @ElenaGarciaHCC',
    handle: '@ElenaGarciaHCC',
    verified: true,
    timestamp: '2025-09-15T16:45:00Z',
    day: 3,
    content: 'Just left the TACE-IO satellite at #CIRSE2025. Pooled data suggests 40% OS improvement with TACE-IO combinations vs TACE alone. Standing room only. LifePearl is the DEB used in both EMERALD-1 and LEAP-012. The combination era belongs to evidence-based DEBs.',
    likes: 823,
    retweets: 378,
    hashtags: ['#CIRSE2025', '#TACE', '#LiverCancer'],
    products: ['prod-1'],
    linkedInsightId: 'ins-27',
  },
  {
    id: 'social-14',
    platform: 'twitter',
    author: 'Liver Cancer Journal @LiverCancerJ',
    handle: '@LiverCancerJ',
    verified: true,
    timestamp: '2025-09-15T11:45:00Z',
    day: 3,
    content: 'Lively debate at #CIRSE2025: When is it too late for DEB-TACE? 72% of audience supports treating selected Child-Pugh B7 patients. ALBI score gaining traction as the preferred liver function assessment. "ALBI grade, not Child-Pugh class" seems to be the emerging consensus.',
    likes: 1289,
    retweets: 567,
    hashtags: ['#CIRSE2025', '#LiverFunction', '#ALBI'],
    products: [],
    linkedInsightId: 'ins-26',
  },
  {
    id: 'social-15',
    platform: 'linkedin',
    author: 'Dr. Maria Santos',
    handle: 'Maria Santos',
    verified: false,
    timestamp: '2025-09-15T18:30:00Z',
    day: 3,
    content: 'End of Day 3 reflections from #CIRSE2025: LifePearl is established as the DEB of choice for the combination era (EMERALD-1, LEAP-012). BioPearl brings a unique re-treatment narrative. The IO field is consolidating around evidence-based DEB platforms. Proud of the Terumo team for an outstanding congress presence.',
    likes: 345,
    retweets: 98,
    hashtags: ['#CIRSE2025', '#InterventionalOncology', '#Terumo'],
    products: ['prod-1', 'prod-2'],
    linkedInsightId: 'ins-25',
  },
  {
    id: 'social-16',
    platform: 'twitter',
    author: 'Dr. Paolo Rossi @PaoloIR_Roma',
    handle: '@PaoloIR_Roma',
    verified: true,
    timestamp: '2025-09-15T14:15:00Z',
    day: 3,
    content: 'The DEB-TACE market share data at #CIRSE2025 is striking. DEB now 67% of all TACE in high-volume European centers (up from 45% in 2020). And total treatment cost is LOWER than cTACE due to fewer re-treatments. The economics support DEB adoption.',
    likes: 445,
    retweets: 198,
    hashtags: ['#CIRSE2025', '#HEOR', '#TACE'],
    products: ['prod-1'],
    linkedInsightId: 'ins-18',
  },
];

export const DAILY_SUMMARIES = [
  {
    day: 2,
    title: 'Day 2 Summary \u2014 CIRSE 2025',
    date: '2025-09-14',
    summary: `## CIRSE 2025 Day 2: TACE-IO Revolution and Technical Excellence

### Key Themes
- **TACE-IO combination paradigm**: The opening plenary established TACE-immunotherapy as the future of intermediate HCC treatment. DEB-TACE preferred over cTACE in combination trials due to standardized, reproducible protocols.
- **LifePearl technical advantages**: Session on microsphere technology highlighted PEG chemistry benefits \u2014 superior suspension time (357s vs 204s), consistent sizing, controlled drug elution.
- **BioPearl excitement**: Degradable microsphere concept generating strong KOL interest for re-treatment optimization.
- **Safety data reassuring**: TACE-IO combination AEs are manageable. LifePearl shows best hepatotoxicity profile among DEBs.

### Coverage by KIT
| KIT | Insights | Status |
|-----|----------|--------|
| Competitive Landscape | 1 | \uD83D\uDFE1 Needs more |
| Combination Therapy | 2 | \uD83D\uDFE2 Good |
| Technical Innovation | 1 | \uD83D\uDFE1 Needs more |
| Clinical Outcomes | 2 | \uD83D\uDFE2 Good |
| Patient Selection | 1 | \uD83D\uDFE1 Needs more |
| Safety & Tolerability | 2 | \uD83D\uDFE2 Good |
| Health Economics | 1 | \uD83D\uDFE1 Needs more |
| Emerging Indications | 2 | \uD83D\uDFE2 Good |

### Hot Insights
1. \uD83D\uDD25 **Opening Plenary TACE-IO** \u2014 Standing room only, 3,000+ attendees. DEB-TACE as immunotherapy partner narrative dominates.
2. \uD83D\uDD25 **Lencioni LifePearl endorsement** (evening reception) \u2014 LifePearl is his "go-to DEB." TACE-first sequencing insight.

### Action Items
- Prepare EMERALD-1 updated evidence summaries for Day 3 presentations
- Follow up with Prof. Lencioni on advisory board participation
- Brief HQ on BCLC-B sub-staging consensus (B1/B2/B3 framework)
- Update competitive tracker with DC Bead LUMI KOL skepticism`,
  },
  {
    day: 3,
    title: 'Day 3 Summary \u2014 CIRSE 2025',
    date: '2025-09-15',
    summary: `## CIRSE 2025 Day 3: EMERALD-1 OS Breakthrough and BioPearl Momentum

### Key Themes
- **EMERALD-1 OS update**: DEB-TACE + durvalumab + bevacizumab extends median OS to 22.7 months (HR 0.72). First Phase 3 to validate TACE-IO combination in intermediate HCC.
- **BioPearl 12-month data**: Complete bead degradation in 85% at 6 months. Successful re-treatment demonstrated. Unique Terumo differentiation.
- **Head-to-head DEB data**: LifePearl ORR 72% vs DC Bead 65% vs HepaSphere 58%. Sustained drug elution advantage confirmed.
- **CBCT as new standard**: CBCT-guided DEB-TACE improves CR rate from 42% to 61%. Non-target embolization reduced by 75%.

### Coverage by KIT
| KIT | Insights | Status |
|-----|----------|--------|
| Competitive Landscape | 3 | \uD83D\uDFE2 Good |
| Combination Therapy | 3 | \uD83D\uDFE2 Excellent |
| Technical Innovation | 3 | \uD83D\uDFE2 Excellent |
| Clinical Outcomes | 3 | \uD83D\uDFE2 Good |
| Patient Selection | 2 | \uD83D\uDFE2 Good |
| Safety & Tolerability | 2 | \uD83D\uDFE2 Good |
| Health Economics | 2 | \uD83D\uDFE2 Good |
| Emerging Indications | 3 | \uD83D\uDFE2 Excellent |

### Hot Insights
1. \uD83D\uDD25 **EMERALD-1 OS update** \u2014 Landmark Phase 3 data validating TACE-IO. LifePearl used in the trial protocol.
2. \uD83D\uDD25 **BioPearl degradation data** \u2014 Unique re-treatment narrative, no competitor can match.
3. \uD83D\uDD25 **Day 3 competitive debrief** \u2014 Team aligned on "LifePearl for combinations, BioPearl for re-treatment."

### Strategic Priorities for Day 4-5
- Update congress talking points with EMERALD-1 OS data and "combination-era DEB" positioning
- Amplify BioPearl re-treatment narrative in clinical specialist discussions
- Seek more Patient Selection insights \u2014 BCLC-B sub-staging is evolving
- Follow up on LEAP-012 PFS signals with Madrid investigator
- Coordinate with HQ on joint value dossier with pharma partners for TACE-IO reimbursement`,
  },
];

export const POINTS_CONFIG = {
  insightCaptured: 10,
  commentAdded: 3,
  likeReceived: 2,
  hotInsightVote: 5,
  hotInsightWinner: 25,
  dailyStreakBonus: 15,
};
